ArticleParasites & vectors2021
Colorectal cancer and Blastocystis sp. infection.
Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06379035 (Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Global prevalence and correlation of intestinal parasitic infections in patients with colorectal cancer: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Global prevalence of intestinal parasites in cancer patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Antiparasitic activity and molecular docking of canthin-6-one derivatives from LED- modulated Eurycoma longifolia roots against Blastocystis ST3 and ST7.Scientific reports · 2026Article
- Prevalence of Blastocystis infection in patients with colorectal cancer in Taiwan.BMC infectious diseases · 2025Article
- Assessment of immunological and hematological parameters in Blastocystis species-infected chronic leukemic patients.Gut pathogens · 2025Article
- Review
- Antiprotozoal Effects ofPathogens (Basel, Switzerland) · 2025Article
- The Role ofPathogens (Basel, Switzerland) · 2025Review
- Helminth-induced immune modulation in colorectal cancer: exploring therapeutic applications.Frontiers in immunology · 2025Review
- Prevalence and molecular identification of protozoan intestinal parasitic infections in cancer patients and a control group.BMC infectious diseases · 2024Article
- An Update onMicroorganisms · 2024Review
- The influence of plant extracts on viability of ST3 and ST7 subtypes of Blastocystis sp.Gut pathogens · 2024Article
- Human protozoa infection and dysplasia in ulcerative colitis: a neglected aspect in a prominent disease.Parasitology research · 2023Article
- Clinicopathological characteristics and its association with digestive system tumors of 1111 patients with Schistosomiasis japonica.Scientific reports · 2023Article
- Levels of Genetic Variants Among Symptomatic Blastocystis Subtypes and their Relationship to Mucosal Immune Surveillance in the Precancerous Colons of Experimentally Infected Rats.Acta parasitologica · 2023Article
- Review
- The associated risk ofFrontiers in oncology · 2023Article
- Review
- Article
- Higher amoebic and metronidazole resistant forms of Blastocystis sp. seen in schizophrenic patients.Parasites & vectors · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBlastocystis sp. is a common intestinal protozoan found worldwide. Based on gene analysis, 17 subtypes (STs, ST1-ST17) have been identified, 9 of which have been isolated from humans. Differences in clinical consequences may depend on differences among the STs. Here, we evaluated the prevalence of Blastocystis sp. in patients with colorectal cancer (CRC) compared to a control group and assessed the relationships between Blastocystis sp. infection and sex; age; and CRC grade, stage, and location.
methodsThe study included 107 CRC patients (41 women and 66 men, median age 65 years); 124 subjects without colorectal cancer or a history of oncological disease comprised the control group (55 women and 69 men, median age 63). Stool samples were collected from patients before oncological treatment and examined using light microscopy (iodine-stained smear). Additionally, PCR-based identification of Blastocystis sp. was performed in 95 stool samples from CRC patients and 76 stool samples from the control group.
resultsLight microscopy showed that the prevalence of Blastocystis sp. was significantly higher in CRC patients than in the control group (12.15% and 2.42%, respectively; p = 0.0041). Multivariate analysis showed that the odds of Blastocystis sp. infection were fivefold higher in the CRC group than in the control group. PCR-based molecular examinations demonstrated that the proportion of patients infected with Blastocystis sp. was significantly higher in the CRC group than in the control group (12.63% and 2.63%, respectively; p = 0.023). The predominant ST in the CRC group was ST3, detected in nine patients (75%), followed by ST1 (2 patients, 16.7%) and ST2 (1 patient, 8.3%). No association was found between Blastocystis sp. infection and age, sex, or CRC stage, grade, or location.
conclusionsThe results showed that CRC was associated with an increased risk of opportunistic Blastocystis sp. infection, even before oncological treatment. To the best of our knowledge, this is the first report estimating the prevalence of Blastocystis sp. infection in CRC patients before oncological treatment in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.